Code Pharma has reported encouraging eight-week results for its HIV drug, Gammora, suggesting a potential to eradicate the virus at the cellular level. As published on BusinessWire, the preliminary findings were shared at the HIV Drug Therapy 2024 Conference in Glasgow, Scotland.
The trial involved 13 ART-naïve participants, randomized into two groups: 7 received 20 mg of Gammora SC alongside Darunavir-based ART, while 6 were treated with ART alone. After eight weeks, all participants experienced a reduction in HIV viral load, with infected cell death observed in the Gammora group. Due to these promising results, the trial is ending earlier than planned, with fewer participants needed.
“These incredibly positive outcomes offer new hope at a time when 40 million individuals worldwide are impacted by HIV and the current standard of care with ART drugs does not offer a cure at the cellular level,” said Eynat Finkelshtein, PhD., Chief Scientific Officer of Code Pharma.